AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22914101 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation 1
Number of subjects: 79
Study 22914101 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation 2
Number of subjects: 79
Study 20946583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bath PUVA and targeted UVB 308 nm excimer radiation
Number of subjects: 22
Study 20946583 — intervention group
Group type: COMPARATOR
Intervention: Bath PUVA alone
Number of subjects: 22
Study 19772696 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca Cola (2.5 litres per day)
Number of subjects: 11
Study 19772696 — intervention group
Group type: COMPARATOR
Intervention: Semi-skimmed milk (2.5 litres per day)
Number of subjects: 11
Study 16420536 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (pressure as low as 8 mmHg)
Number of subjects: 0
Study 16420536 — intervention group
Group type: COMPARATOR
Intervention: No stockings
Number of subjects: 0
Study 15585144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) combined with extracorporeal membrane oxygenation (ECMO)
Number of subjects: 8
Study 15585144 — intervention group
Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF) alone
Number of subjects: 8
Study 15585144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) with ECMO
Number of subjects: 8
Study 15585144 — intervention group
Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 8
Study 12027046 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg p.o.)
Number of subjects: 58
Study 12027046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 9315401 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron
Number of subjects: 30
Study 9315401 — intervention group
Group type: COMPARATOR
Intervention: Expectant therapy with metoclopramide
Number of subjects: 30
Study 9315401 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced radiation fields (dog-leg RT)
Number of subjects: 30
Study 9315401 — intervention group
Group type: COMPARATOR
Intervention: Antiemetic use in expectant therapy groups
Number of subjects: 30
Study 9315401 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including ondansetron)
Number of subjects: 30
Study 8330429 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate Sodium
Number of subjects: 0
Study 8330429 — intervention group
Group type: COMPARATOR
Intervention: Naproxen Sodium
Number of subjects: 0
Study 2872720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluoxymesterone (1 mg/kg/d)
Number of subjects: 235
Study 2872720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose norethandrolone (1 mg/kg/d)
Number of subjects: 235
Study 2872720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluoxymesterone (0.2 mg/kg/d)
Number of subjects: 235
Study 2872720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose norethandrolone (0.2 mg/kg/d)
Number of subjects: 235
Study 2872720 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of 4 different androgens
Number of subjects: 235
Study 2872720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (1 mg/kg/d) for 18 months
Number of subjects: 235
Study 29193980 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal cream 0.003% (15 μg estradiol; 0.5 g cream), applied vaginally once daily for 2 weeks followed by two applications/week for 10 weeks.
Number of subjects: 576
Study 29193980 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal cream 0.003%
Number of subjects: 576
Study 29193980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 g cream), applied vaginally once daily for 2 weeks followed by two applications/week for 10 weeks.
Number of subjects: 576
Study 27145084 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 0
Study 27145084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 27145084 — intervention group
Group type: EXPERIMENTAL
Intervention: High 2D:4D group
Number of subjects: 0
Study 27145084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 2D:4D group
Number of subjects: 0
Study 25028375 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) treatment for 3 years
Number of subjects: 61
Study 21881530 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-week strength training program (maximal strength training, explosive strength training, golf-specific strength training)
Number of subjects: 10
Study 21881530 — intervention group
Group type: COMPARATOR
Intervention: Standard physical conditioning program for golf (Control Group)
Number of subjects: 10
Study 20819415 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (elastic band exercise at moderate intensity five times per week)
Number of subjects: 44
Study 20819415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking for 60 min at moderate intensity five times per week)
Number of subjects: 44
Study 20819415 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary lifestyle)
Number of subjects: 44
Study 18539688 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary education programme
Number of subjects: 300
Study 18539688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 15882537 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/HCTZ 12.5 mg daily
Number of subjects: 124
Study 15882537 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 60 mg daily
Number of subjects: 124
Study 12795769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (0.025 mg/kg, 0.075 mg/kg, or 0.150 mg/kg)
Number of subjects: 229
Study 12795769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 12795769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 229
Study 12795729 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of telephone or web‐based provider‐specific information to aid in the selection of a provider
Number of subjects: 1090
Study 12795729 — intervention group
Group type: COMPARATOR
Intervention: Control group (assigned to a PCP)
Number of subjects: 1090
Study 9534499 — intervention group
Group type: EXPERIMENTAL
Intervention: Early labor assessment
Number of subjects: 209
Study 9534499 — intervention group
Group type: COMPARATOR
Intervention: Direct admission to hospital
Number of subjects: 209
Study 7713829 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (LO)
Number of subjects: 8
Study 7713829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HI)
Number of subjects: 8
Study 7713829 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NX)
Number of subjects: 8
Study 2670029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilised amnion
Number of subjects: 40
Study 2670029 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen amnion
Number of subjects: 40
Study 2670029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh amnion
Number of subjects: 40
Study 2670029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-culture-maintained amnion
Number of subjects: 40
Study 790118 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (R) 15 methyl prostaglandin E2, 150 mug orally every 6 hours for two weeks
Number of subjects: 10
Study 790118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study 28866911 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + booster group
Number of subjects: 108
Study 28866911 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT only group
Number of subjects: 108
Study 28866911 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 108
Study 27899759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment aiming for systolic BP 120-140 mmHg
Number of subjects: 100
Study 27899759 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment aiming for systolic BP 140-180 mmHg
Number of subjects: 100
Study 27899759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 100
Study 27899759 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100
Study 24635483 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) for solar keratosis (SK) grade I-II.
Number of subjects: 20
Study 23809328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8g of c9,t11CLA daily for two months
Number of subjects: 0
Study 23809328 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6g of c9,t11CLA daily for two months
Number of subjects: 0
Study 23809328 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2g of c9,t11CLA daily for two months
Number of subjects: 0
Study 22352278 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 59
Study 22352278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 59
Study 22352278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 59
Study 22352278 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 59
Study 19567487 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported upper extremity exercise training (UEET) plus pulmonary rehabilitation (PR)
Number of subjects: 50
Study 19567487 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR) alone
Number of subjects: 50
Study 17004019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered intervention via a centralised telephone service
Number of subjects: 500
Study 17004019 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 500
Study 15099409 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with LC n‐3 PUFA
Number of subjects: 0
Study 15099409 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐n‐6 PUFA background diet with fish oil supplementation
Number of subjects: 0
Study 10827393 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment initiated within the first 1.5 hours (group A)
Number of subjects: 358
Study 10827393 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early fibrinolytic therapy
Number of subjects: 358
Study 11696900 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (3M Dental Products Division)
Number of subjects: 40
Study 11696900 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single-Component (Vivadent)
Number of subjects: 40
Study 11696900 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond 2.1 (Dentsply DeTrey)
Number of subjects: 40
Study 11696900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenure Quik with Fluoride (Den-Mat Co.)
Number of subjects: 40
Study 8138828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin (ACTH)
Number of subjects: 2
Study 8138828 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DEX)
Number of subjects: 2
Study 29562906 — intervention group
Group type: EXPERIMENTAL
Intervention: MHFA eLearning course (n = 27)
Number of subjects: 55
Study 29562906 — intervention group
Group type: COMPARATOR
Intervention: No-access control group (n = 28)
Number of subjects: 55
Study 26349772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone days 1-3
Number of subjects: 80
Study 26349772 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone day 1
Number of subjects: 80
Study 23868685 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) - 4-week training program (3 days/week), consisting of 4 s simultaneous maximal voluntary contractions of elbow flexors and extensors at 90° of the elbow joint, followed by 4 s muscle relaxation (10 repetitions/set, 5 sets/day)
Number of subjects: 23
Study 23868685 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 22445432 — intervention group
Group type: EXPERIMENTAL
Intervention: Male condom
Number of subjects: 108
Study 22445432 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom
Number of subjects: 108
Study 20169410 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol PBI
Number of subjects: 978
Study 20169410 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Alcohol + Sex PBI
Number of subjects: 978
Study 20169410 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 978
Study 20169410 — intervention group
Group type: COMPARATOR
Intervention: Unmeasured Control
Number of subjects: 978
Study 17888558 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mg GTPs
Number of subjects: 124
Study 17888558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000‐mg GTPs
Number of subjects: 124
Study 17888558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 15950853 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 1.0% ropivacaine with 1:200,000 epinephrine and analgesia with 0.2% ropivacaine at 8 mL/h, maintained for 7 days
Number of subjects: 38
Study 15950853 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with 0.5% bupivacaine and analgesia with intravenous patient‐controlled analgesia morphine, demand mode only
Number of subjects: 38
Study 12703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group Propo)
Number of subjects: 50
Study 12703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital and Isoflurane (Group Metho-Iso)
Number of subjects: 50
Study 12703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dreaming patients
Number of subjects: 50
Study 12703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dreaming patients
Number of subjects: 50
Study 10569604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg desmopressin
Number of subjects: 33
Study 10569604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg desmopressin
Number of subjects: 33
Study 10569604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic treatment
Number of subjects: 33
Study 10569604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8935931 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.03 mL/Kg of 5 mg/mL solution)
Number of subjects: 100
Study 8935931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 1714886 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) at 100 mg/M2 daily for 5 days and etoposide at 200 mg/M2 daily for the first 3 days of therapy
Number of subjects: 57
Study 1714886 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) and etoposide plus azacitidine (AZ) at a dosage of 250 mg/M2 on days 4 and 5
Number of subjects: 57
Study 1714886 — intervention group
Group type: COMPARATOR
Intervention: Amsacrine (AMSA) and etoposide
Number of subjects: 57
Study 6349288 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert extinction
Number of subjects: 21
Study 6349288 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 21
Study 6349288 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (Control)
Number of subjects: 21
Study 31318261 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Time (PT)
Number of subjects: 141
Study 31318261 — intervention group
Group type: COMPARATOR
Intervention: Interparental Conflict (IPC)
Number of subjects: 141
Study 30326035 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored patient navigator intervention
Number of subjects: 223
Study 30326035 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study 27264120 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1918
Study 27264120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1918
Study 25201459 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg for 4 weeks
Number of subjects: 60
Study 25201459 — intervention group
Group type: COMPARATOR
Intervention: placebo for 4 weeks
Number of subjects: 60
Study 22240282 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 400mg bid
Number of subjects: 226
Study 22240282 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 226
Study 19729318 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 157
Study 19729318 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 157
Study 17403742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch (SE) adhesive
Number of subjects: 25
Study 17403742 — intervention group
Group type: COMPARATOR
Intervention: Etch-and-rinse (ER) adhesive
Number of subjects: 25
Study 15829478 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher incentives group (Can dollars 15 electronic gift certificate)
Number of subjects: 14
Study 15829478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower incentive group (Can dollars 5 gift certificate)
Number of subjects: 14
Study 15829478 — intervention group
Group type: EXPERIMENTAL
Intervention: General Internet community (not specified incentive)
Number of subjects: 14
Study 15829478 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend referrals (snowball strategy)
Number of subjects: 14
Study 15829478 — intervention group
Group type: COMPARATOR
Intervention: Defined community recruitment (Can dollars 20 electronic gift certificate)
Number of subjects: 14
Study 12441222 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 30
Study 12441222 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (10 mg)
Number of subjects: 30
Study 9653491 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine + RCT (n = 25)
Number of subjects: 39
Study 9653491 — intervention group
Group type: COMPARATOR
Intervention: RCT alone (n = 14)
Number of subjects: 39
Study 8593193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 stabilized with 2.08% sodium gluconate
Number of subjects: 549
Study 8593193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 stabilized with 4.16% sodium gluconate
Number of subjects: 549
Study 8593193 — intervention group
Group type: COMPARATOR
Intervention: 0.243% NaF control dentifrice
Number of subjects: 549
Study 8593193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 dentifrices
Number of subjects: 549
Study 2669536 — intervention group
Group type: EXPERIMENTAL
Intervention: Left unilateral ECT
Number of subjects: 30
Study 2669536 — intervention group
Group type: COMPARATOR
Intervention: Right unilateral ECT
Number of subjects: 30
Study 1225368 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 dB, 1000 Hz orienting tones (condition 1)
Number of subjects: 0
Study 1225368 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 dB, 1000 and 2000 Hz tones requiring a motor response to the 1000 Hz tone (signal tone, condition 2)
Number of subjects: 0
Study 1225368 — intervention group
Group type: EXPERIMENTAL
Intervention: 85 dB, 1000 Hz orienting tones (condition 3)
Number of subjects: 0
Study 1225368 — intervention group
Group type: COMPARATOR
Intervention: 75 dB tones (control group for non-psychotic psychiatric patients)
Number of subjects: 0
Study 31941548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaping cues (exposure to vaping videos)
Number of subjects: 936
Study 31941548 — intervention group
Group type: COMPARATOR
Intervention: Neutral cues (exposure to neutral videos)
Number of subjects: 936
Study 31941548 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cues (exposure to smoking videos)
Number of subjects: 936
Study 31060627 — intervention group
Group type: COMPARATOR
Intervention: OLV + CPAP
Number of subjects: 30
Study 31060627 — intervention group
Group type: EXPERIMENTAL
Intervention: OLV + DLV
Number of subjects: 30
Study 27811309 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole)
Number of subjects: 3096
Study 27811309 — intervention group
Group type: COMPARATOR
Intervention: Guideline treatment (control group)
Number of subjects: 3096
Study 27827816 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab combined with doxorubicin
Number of subjects: 0
Study 27827816 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study 24763910 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 20
Study 24763910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22205191 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 60
Study 22205191 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 60
Study 22205191 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 60
Study 19416499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) only
Number of subjects: 808
Study 19416499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and Copper (Zn+Cu)
Number of subjects: 808
Study 19416499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 808
Study 17950796 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 0
Study 17950796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15752381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine + Ketoconazole (20 mg qd + 450 mg qd)
Number of subjects: 117
Study 15752381 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine + Ketoconazole (10 mg qd + 400 mg qd)
Number of subjects: 117
Study 15752381 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole + Placebo (450 mg qd or 400 mg qd)
Number of subjects: 117
Study 15752381 — intervention group
Group type: COMPARATOR
Intervention: Ebastine + Placebo (20 mg qd)
Number of subjects: 117
Study 15752381 — intervention group
Group type: COMPARATOR
Intervention: Loratadine + Placebo (10 mg qd)
Number of subjects: 117
Study 12110818 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP Autohaler at half the daily dose (100-200 microg)
Number of subjects: 520
Study 12110818 — intervention group
Group type: COMPARATOR
Intervention: CFC‐BDP+S (200-400 microg)
Number of subjects: 520
Study 12110818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HFA‐BDP and CFC‐BDP+S)
Number of subjects: 520